Todos Medical Ltd CEO Gerald Commissiong tells Proactive its majority-owned subsidiary 3CL Pharma Ltd announced that its mechanism-based 3CL protease inhibitors Tollovir and Tollovidthat target the active site of the 3CL protease -- showing robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC). Additionally, the company said Tollovir and Tollovid showed inhibitory activity against the original wild-type SARS-CoV-2 strain, as well as the Alpha, Beta, Delta, and Gamma VOCs.
Todos Medical says Tollovir and Tollovid show robust inhibitory activity against 3CL protease
